T3 augmentation in major depressive disorder: Safety considerations

American Journal of Psychiatry

Volumn 168, Issue 10, 2011, Pages 1035-1040

  Rosenthal, Lisa J ^a,b,c   Goldner, Whitney S ^a,b,c   O'Reardon, John P ^a,b,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DEIODINASE TYPE 1; ESCITALOPRAM; FLUOXETINE; LEVOTHYROXINE; LIOTHYRONINE; LITHIUM; METFORMIN; OXIDOREDUCTASE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THYROTROPIN; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE;

ADULT; ANERGY; ANHEDONIA; ARTICLE; BIPOLAR DISORDER; BLOOD PRESSURE REGULATION; BONE DENSITY; CASE REPORT; CELL NUCLEUS; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DIO1 GENE; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAPHY; ENDOCRINOLOGY; ENERGY METABOLISM; FAMILY HISTORY; GENE; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; HEART ATRIUM ARRHYTHMIA; HEART PALPITATION; HIGH RISK PATIENT; HORMONE ACTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTHYROIDISM; HYPOTHYROIDISM; LOW DRUG DOSE; MAJOR DEPRESSION; MALE; MEDICAL RECORD; MONOTHERAPY; MORBID OBESITY; NEPHROLITHIASIS; NERVOUSNESS; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; REMISSION; SEROTONINERGIC TRANSMISSION; SIDE EFFECT; SINUS TACHYCARDIA; SLEEP DISORDER; SWEATING; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; DRUG TOXICITY;

ADULT; DEPRESSIVE DISORDER, MAJOR; DRUG TOXICITY; HUMANS; MALE; TRIIODOTHYRONINE;

EID: 80054816391     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2011.10030402     Document Type: Article

References (41)

1. Arem R, Cusi K: Thyroid function testing in psychiatric illness: usefulness and limitations. Trends Endocrinol Metab 1997; 8:282-287 (Pubitemid 27424206)
2. Wilson JD, Foster DW (eds): Williams Textbook of Endocrinology, 8th ed. Philadelphia, WB Saunders, 1992
3. Lifschytz T, Segman R, Shalom G, Lerer B, Gur E, Golzer T, Newman ME: Basic mechanisms of augmentation of antidepressant effects with thyroid hormone. Curr Drug Targets 2006; 7:203-210
4. Joffe RT, Singer W: A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants. Psychiatry Res 1990; 32:241-251 (Pubitemid 20214380)
5. Cooper-Kazaz R, van der Deure WM, Medici M, Visser TJ, Alkelai A, Glaser B, Peeters RP, Lerer B: Preliminary evidence that a functional polymorphism in type 1 deiodinase is associated with enhanced potentiation of the antidepressant effect of sertraline by triiodothyronine. J Affect Disord 2009; 116:113-116
6. Gur E, Lerer B, Newman ME: Chronic clomipramine and triiodothyronine increase serotonin levels in rat frontal cortex in vivo: relationship to serotonin autoreceptor activity. J Pharmacol Exp Ther 1999; 288:81-87 (Pubitemid 29113476)
7. Bauer M, Heinz A, Whybrow PC: Thyroid hormones, serotonin, and mood: of synergy and significance in the adult brain. Mol Psychiatry 2002; 7:140-156 (Pubitemid 34177782)
8. Prange AJ Jr, Wilson IC, Rabon AM, Lipton MA: Enhancement of imipramine antidepressant activity by thyroid hormone. Am J Psychiatry 1969; 126:457-469
9. Altshuler LL, Bauer M, Frye MA, Gitlin MJ, Mintz J, Szuba MP, Leight KL, Whybrow PC: Does thyroid supplementation accelerate tricyclic antidepressant response? a review and meta-analysis of the literature. Am J Psychiatry 2001; 158:1617-1622 (Pubitemid 32923653)
10. Aronson R, Offman HJ, Joffe RT, Naylor CD: Triiodothyronine augmentation in the treatment of refractory depression: a meta-analysis. Arch Gen Psychiatry 1996; 53:842-848 (Pubitemid 26303624)
11. Wheatley D: Potentiation of amitriptyline by thyroid hormone. Arch Gen Psychiatry 1972; 26:229-233
12. Coppen A, Whybrow PC, Noguera R, Maggs R, Prange AJ Jr: The comparative antidepressant value of L-tryptophan and imipramine with and without attempted potentiation by liothyronine. Arch Gen Psychiatry 1972; 26:234-241
13. Feighner JP, King LJ, Schuckit MA, Croughan J, Briscoe W: Hormonal potentiation of imipramine and ECT in primary depression. Am J Psychiatry 1972; 128:1230-1238
14. Thase ME, Kupfer DJ, Jarrett DB: Treatment of imipramine resistant recurrent depression, I: an open clinical trial of adjunctive L-triiodothyronine. J Clin Psychiatry 1989; 50:385-388 (Pubitemid 19267920)
15. Joffe RT, Singer W, Levitt AJ, MacDonald C: A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993; 50:387-393 (Pubitemid 23143128)
16. 3 to potentiate tricyclic antidepressant response. J Affect Disord 1987; 13:267-272
17. Banki CM: Cerebrospinal fluid amine metabolites after combined amitriptyline-triiodothyronine treatment of depressed women. Eur J Clin Pharmacol 1977; 11:311-315
18. Cooper-Kazaz R, Lerer B: Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors. Int J Neuropsychopharmacol 2008; 11:685-699 (Pubitemid 351931816)
19. Papakostas GI, Cooper-Kazaz R, Appelhof BC, Posternak MA, Johnson DP, Klibanski A, Lerer B, Fava M: Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies. Int Clin Psychopharmacol 2009; 24:19-25
20. 3 augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006; 163:1519-1530
21. Cooper-Kazaz R, Apter JT, Cohen R, Karagichev L, Muhammed-Moussa S, Grupper D, Drori T, Newman ME, Sackeim HA, Glaser B, Lerer B: Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 2007; 64:679-688 (Pubitemid 46878668)
22. Appelhof BC, Brouwer JP, van Dyck R, Fliers E, Hoogendijk WJ, Huyser J, Schene AH, Tijssen JG, Wiersinga WM: Triiodothyronine addition to paroxetine in the treatment of major depressive disorder. J Clin Endocrinol Metab 2004; 89:6271-6276 (Pubitemid 39628444)
23. Gyulai L, Bauer M, Garcia-Espana F, Hierholzer J, Baumgartner A, Berghöfer A, Whybrow PC: Bone mineral density in pre-and post-menopausal women with affective disorder treated with long-term L-thyroxine augmentation. J Affect Disord 2001; 66:185-191 (Pubitemid 32907524)
24. 3 in refractory major depression. J Affect Disord 2009; 115:230-233
25. Baskin HJ, Cobin RH, Duick DS, Gharib H, Guttler RB, Kaplan MM, Segal RL; American Association of Clinical Endocrinologists: American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract 2002; 8:457-469
26. Clyde PW, Harari AE, Getka EJ, Shakir KM: Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial. JAMA 2003; 290:2952-2958 (Pubitemid 37505527)
27. Siegmund W, Spieker K, Weike AI, Giessmann T, Modess C, Dabers T, Kirsch G, Sänger E, Engel G, Hamm AO, Nauck M, Meng W: Replacement therapy with levothyroxine plus triiodothyronine (bioavailable molar ratio 14:1) is not superior to thyroxine alone to improve well-being and cognitive performance in hypothyroidism. Clin Endocrinol (Oxf) 2004; 60:750-757 (Pubitemid 38788084)
28. Appelhof BC, Fliers E, Wekking EM, Schene AH, Huyser J, Tijssen JG, Endert E, van Weert HC, Wiersinga WM: Combined therapy with levothyroxine and liothyronine in two ratios, compared with levothyroxine monotherapy in primary hypothyroidsm: a double-blind randomized, controlled clinical trial. J Clin Endocrinol Metab 2005; 90:2666-2674 (Pubitemid 40686307)
29. Escobar-Morreale HF, Botella-Carretero JI, Gómez-Bueno M, Galán JM, Barrios V, Sancho J: Thyroid hormone replacement therapy in primary hypothyroidism: a randomized trial comparing L-thyroxine plus liothyronine with L-thyroxine alone. Ann Intern Med 2005; 142:412-424
30. Escobar-Morreale HF, Botella-Carretero JI, Escobar del Rey F, Morreale de Escobar G: Review: treatment of hypothyroidism with combinations of levothyroxine plus liothyronine. J Clin Endocrinol Metab 2005; 90:4946-4954 (Pubitemid 41159395)
31. Ma C, Xie J, Huang X, Wang G, Wang Y, Wang X, Zuo S: Thyroxine alone or thyroxine plus triiodothyronine replacement therapy for hypothyroidism. Nucl Med Commun 2009; 30:586-593
32. 4 monotherapy in patients with hypothyroidism: a double blind, randomized cross-over study. Eur J Endocrinol 2009; 161:895-902
33. Osei K, Falko JM, O'Dorisio TM, Adam DR: Decreased serum C-peptide/insulin molar ratios after oral glucose ingestion in hyperthyroid patients. Diabetes Care 1984; 7:471-475 (Pubitemid 14048617)
34. Uzzan B, Campos J, Cucherat M, Nony P, Boissel JP, Perret GY: Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 1996; 81:4278-4289 (Pubitemid 26412030)
35. Faber J, Galløe AM: Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol 1994; 130:350-356 (Pubitemid 24135720)
36. Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke GL, Tracy RP, Ladenson PW: Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 2006; 295:1033-1041
37. Wiersinga WM: Propranolol and thyroid hormone metabolism. Thyroid 1991; 1:273-277
38. American Psychiatric Association: Practice Guideline for the Treatment of Patients With Major Depressive Disorder, 3rd ed. Am J Psychiatry 2010; 167(Oct suppl)
39. Schatzberg AF, Cole JO, DeBattista C: Augmentation strategies for treatment-resistant disorders, in Manual of Clinical Psychopharmacology, 7th ed. American Psychiatric Publishing, 2010, pp 500-544
40. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163:1905-1917 (Pubitemid 44807782)
41. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R: Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008; 358:252-260